ADOCIA Aktie

 

LYON, France--(BUSINESS WIRE)--#BIOTECH--Regulatory News: Under the liquidity agreement entrusted by Adocia (Euronext Paris: FR0011184241 – ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account on June 30, 2026 : Number of shares: 45,699 Cash balance of the liquidity account: € 126,636.84 During the 1st half of 2026, a total of: Buy-side 298,013 shares € 1,619,929.17 1,640 transactions Sell-side 279,243 shares € 1,571,808.67 1,524 transactions The following resources appeared on the last half year statement on December 31, 2025 on the liquidity account: Number of shares: 26,929 Cash balance of the liquidity account: € 173,857.41 The following resources appeared on the liquidity account when the activity started: Number of shares: 15,026 Cash balance of the liquidity account: € 300,000.00 The liquidity agreement complies with AMF Decision n° 2021-01 of June 22nd, 2021, renewing the implementation of liquidity contracts for shares as an accepted market pr...

Cash position of €12.0 million as of March 31, 2026 Shareholder loan agreement signed with Vester Finance on April 21, 2026, securing a cash runway until the beginning of Q2 2027 BioChaperone®: strategic priority given to BioChaperone® as feasibility studies have yielded positive results, and a new study has been initiated AdoShell®: suspension of the submission of the clinical trial application originally scheduled for Q3 2026 Board of Directors: Stéphane Boissel appointed as Chairman and Jacky Vonderscher co-opted as Director LYON, France--(BUSINESS WIRE)--#BIOTECH--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the first quarter of 2026 and provides a business update. “As the market for metabolic peptides evolves toward peptide combinations, BioChaperone® is establishi...

LYON, France--(BUSINESS WIRE)--#BIOTECH--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announced today that it will hold its annual shareholders' meeting (“AGM”) on June 3rd, 2026, at 10:00 am, at the offices of Jones Day, Hotel de Talleyrand, 2 rue Saint Florentin, 75001 Paris. The notice of this shareholders' meeting, which serves as the convening notice was published on April 27th, 2026 in the French Bulletin des Annonces Légales Obligatoires (“BALO”). It includes the agenda, the proposed resolutions and instructions for participating and voting at this meeting. In accordance with the regulations in force, all documentation concerning the meeting is available to shareholders on the Company's website: https://www.adocia.com/investors/general-meeting/ The online voting platform will open on May 18, 2026, at 12:00 p...

Cash position of €17.2m as of December 31, 2025 Progresses achieved with our flagship projects in 2025: Chinese partner Tonghua Dongbao completed BioChaperone® Lispro Phase 3 program with positive results in people with type 1 and type 2 diabetes in China, and the marketing authorization filling is in preparation Continued development of BioChaperone®, with two new feasibility studies in collaboration with two large pharmaceutical companies in the fields of diabetes and obesity Patent application filed for a new long-acting technology platform AdoXLong™, with initial positive in vitro and in vivo results generated with semaglutide Continued development of AdoShell® platform, with a clinical trial application submission to regulatory authorities planned for Q3 2026 Post-period events: A shareholder loan agreement was entered into on April 21, 2026 with Vester Finance, securing a cash runway until the begining of Q2 2027 New Board of Directors structure with Stephane Boissel appointed as Chairman in ...

Signing of a two-year shareholder loan agreement for up to €6.0 million, of which €1.5 million paid upon signing, repayable in new shares representing up to 7.6% of the Company's share capital or in cash This shareholder operation secures the cash runway until beginning Q2 2027 LYON, France--(BUSINESS WIRE)--#BIOTECH--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced the establishment of a shareholder loan agreement with Vester Finance, repayable in new shares, with an option for the Company to repay in cash under certain conditions. "We are delighted to complete this transaction proposed by Vester Finance as he is the largest shareholder after the Soula co-founders and has been involved in most of our financing transactions and fundraising campaigns over the past four years. In addition...

Chinese partner Tonghua Dongbao completed BioChaperone® Lispro Phase 3 program with positive data on people with type 1 diabetes, completing the positive results obtained on type 2 diabetes Continued development of BioChaperone® to stabilize and combine peptides for the treatment of obesity and diabetes, with two ongoing feasibility studies in collaboration with two large pharmaceutical companies Patent filed for a new technology platform AdoXLongTM that would allow once monthly peptide injections to treat obesity and diabetes, with initial positive in vitro and in vivo results generated with semaglutide Cash position of €17.2 million as of December 31, 2025, securing cash runway until beginning 2027, thanks to a €10 million fundraising completed in December 2025 Gérard Soula to step down as Chairman of the Board of Directors, in accordance with the statutory age limit, Stéphane Boissel has been appointed Chairman of the Board, and Jacky Vonderscher has been co-opted as a Director LYON, France--(B...

Cash position of €7.1m (million) as of June 30, 2025 following successful completion of €9.7m private placement in February 2025 Cash runway secured until Q2 2026 considering the US$10 million milestone payment from partner Tonghua Dongbao and 2024 Research Tax Credit of €2.8 million, both received in July 2025 Recent advances on flagship product pipeline: BioChaperone® Lispro read out positive Phase 3 top-line data in China in people with Type 2 Diabetes and results in Type 1 Diabetes expected in Q4 2025 BioChaperone® and BC CagriSema: business priority given to establishing partnerships, while generating additional differentiated data AdoShell®: proof-of-concept established on insulin-secreting stem cells and priority given to find a partner submission of the clinical trial application with human islets now expected in Q3 2026 LYON, France--(BUSINESS WIRE)--#BIOTECH--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company fo...

Cash position of €7.1 million as of June 30, 2025 US$10 million milestone payment from partner Tonghua Dongbao and 2024 Research Tax Credit of €2.8 million received in July 2025 Current cash position secures runway until Q2 2026 LYON, France--(BUSINESS WIRE)--#BIOTECH--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2025 and provides a business update. "Over the past six months, significant progress has been achieved on both AdoShell® and BioChaperone® CagriSema. Meanwhile, the arrival of semaglutide biosimilars accross many countries in 2026 presents a new opportunity for AdOral® Sema, broadening the field of possible partners. For M1Pram, we are continuing our discussions to finance and launch a Phase 2b study in the USA. Thanks to a healthy cash...

LYON, France--(BUSINESS WIRE)--#BIOTECH--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”), ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of May 31st, 2025. Month Date Total number of outstanding shares Total number of theoretical voting rights (1) Total number of exercisable voting rights (2) May 05/31/2025 18,087,690 20,213,633 20,168,948 (1) The total number of theoretical voting rights is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Arti...